Gi-Young Sohn
Director Ejecutivo en ENZYCHEM LIFESCIENCES CORPORATION .
Fortuna: 6 M $ al 30/04/2024
Cargos activos de Gi-Young Sohn
| Empresas | Cargo | Inicio | Fin |
|---|---|---|---|
| ENZYCHEM LIFESCIENCES CORPORATION | Director/Miembro de la Junta | - | - |
| Director Ejecutivo | 01/06/2012 | - | |
| Presidente | 01/06/2012 | - | |
Bridget Lifesciences Corp.
 Bridget Lifesciences Corp. Financial ConglomeratesFinance Bridget Lifesciences Corp. functions as an investment holding South Korean company. Hye-Kyung Kim has been the CEO of the private company since 2003. | Presidente | 01/01/2003 | - |
Historial de carrera de Gi-Young Sohn
Formación de Gi-Young Sohn.
| Korea University | Graduate Degree |
Estadísticas
Internacional
| Corea del Sur | 4 |
Operativa
| Chairman | 2 |
| Director/Board Member | 1 |
| Chief Executive Officer | 1 |
Sectorial
| Health Technology | 2 |
| Consumer Services | 2 |
| Finance | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
| Empresas cotizadas | 1 |
|---|---|
| ENZYCHEM LIFESCIENCES CORPORATION | Health Technology |
| Empresas privadas | 1 |
|---|---|
Bridget Lifesciences Corp.
Bridget Lifesciences Corp. Financial ConglomeratesFinance Bridget Lifesciences Corp. functions as an investment holding South Korean company. Hye-Kyung Kim has been the CEO of the private company since 2003. | Finance |
- Bolsa de valores
- Insiders
- Gi-Young Sohn
- Experiencia
